Cite
HARVARD Citation
Jabbour, E. et al. (2020). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia research. p. . [Online].